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Abstract The existence of “tumor-initiating cells” (TICs)
has been a topic of heated debate for the last few years
within the field of cancer biology. Their continuous
characterization in a variety of solid tumors has led to an
abundance of evidence supporting their existence. TICs are
believed to be responsible for resistance against conven-
tional treatment regimes of chemotherapy and radiation,
ultimately leading to metastasis and patient demise. This
review summarizes DNA repair mechanism(s) and their
role in the maintenance and regulation of stem cells. There
is evidence supporting the hypothesis that TICs, similar to
embryonic stem (ES) cells and hematopoietic stem cells
(HSCs), display an increase in their ability to survive
genotoxic stress and injury. Mechanistically, the ability of
ES cells, HSCs and TICs to survive under stressful
conditions can be attributed to an increase in the efficiency
at which these cells undergo DNA repair. Furthermore, the
data presented in this review summarize the results found
by our lab and others demonstrating that TICs have an
increase in their genomic stability, which can allow for TIC
survival under conditions such as anticancer treatments,
while the bulk population of tumor cells dies. We believe
that these data will greatly impact the development and
design of future therapies being engineered to target and
eradicate this highly aggressive cancer cell population.
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1 Introduction
Cancer is defined as uncontrolled cell growth resulting
from genetic mutations or exposure to environmental
carcinogens that alter normal regulation. The uncontrolled
cellular growth results in the formation of a mass of cells
commonly referred to as a tumor. The majority of cells
within a tumor share identical genetic and epigenetic gene
signatures; however, there is a subset of cells that exist
within the total population and carry unique signatures, thus
demonstrating tumor heterogeneity. This process of tumor
heterogeneity can be explained by two different models: the
stochastic model and the hierarchy model (Fig. 1, adapted
from [1]). The stochastic model hypothesizes that a tumor
is biologically homogenous and both intrinsic and extrinsic
factors affect cell behavior, leading to heterogeneous
populations of cells. The hierarchy model hypothesizes that
there are biologically distinct cells within the tumor, and it
is this specific population of cells that is responsible for the
initiation of tumor growth. The existence of these “tumor-
initiating cells” (TICs) has been a topic of vigorous
discussion for the last few years within the field of cancer
biology. Their continuous characterization has led to an
abundance of data supporting their existence; additionally,
there is evidence suggesting that these cells are responsible
for chemo- and radioresistance, hence serving as the
foundation for metastasis and ultimately patient demise.
Recently, our laboratory and others have observed that
TICs have an increase in their genomic stability that allows
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DOI 10.1007/s10555-011-9277-0them to have an enhanced ability to survive against
treatment compared to the bulk population of cells. The
following review will summarize evidence supporting the
hypothesis that TICs, similar to embryonic stem (ES) cells
and hematopoietic stem cells (HSCs), have an increase in
their ability to deal with genotoxic stress and injury which
appears to be due to an increase in the efficiency of DNA
repair mechanism(s).
1.1 Tumor-initiating cells
TICs represent a small population of cells that exist within a
heterogeneous tumor based on the hierarchical theory of
cancer development. Currently, TICs have been isolated
from a variety of solid tumor types, including those from
the bladder, brain, breast, colon, head/neck, liver, lung,
ovary, pancreas, prostate, and skin [2–6]. Within the last
few years, it has also been well documented that very low
numbers of TICs (10–100) have the ability to form colonies
in vitro or initiate tumor formation in vivo [7–12]. To
achieve this same effect with total tumor cells, one to ten
million cells are required. As early as 1994, Lapidot et al.
[13] showed that “stem cells” could be isolated using
fluorescence-activated cell sorting (FACS) based on the
expression of the cell surface markers CD34 and CD38.
The CD34
+CD38
− cells were identified as potential stem
cells of acute myeloid leukemia. This “stem cell” pheno-
type was assigned since non-obese diabetes/severe com-
bined immunodeficiency mice injected with low numbers
of CD34
+CD38
− cells developed leukemia, whereas those
injected with even larger numbers of more mature cells
(CD34
−CD38
+) did not [13]. Overall, TICs are capable of
undergoing the process of self-renewal and giving rise to
differentiated tumor cells, while the bulk of tumor cells is
highly differentiated, has limited proliferative potential, and
is non-tumorigenic.
Fig. 1 Process of tumor hetero-
geneity can be explained by two
different models (adapted from
[1]). a In the stochastic model,
each cell from a heterogeneous
tumor has the ability to form a
new heterogeneously differenti-
ated tumor. b In the hierarchical
model, not all tumor cells have
the ability to form a new hetero-
geneous differentiated tumor,
and rather only the tumor-
initiating cell or TIC does
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including FACS based on cell surface expression of CD44,
CD133, α2β1 integrin for example, as well as flow
cytometry-based “side populations” (reviewed by [14]).
Additionally, TICs can be isolated by generating spheroids
using specialized culture conditions and highly defined
media called stem cell media [15–18]. Spheres generally
express higher levels of stem cell genes and demonstrate
higher tumorigenic potential in animals with similar levels
to sorted TICs compared to total cells [17–21]. Our lab has
also established a method to isolate these TICs based on the
property of increased invasive ability [22]. Using an in vitro
Matrigel assay and highly defined media [22, 23], we have
isolated prostate TICs that have a stem-like phenotype [22],
have undergone an epithelial-to-mesenchymal transition
during the process of invasion, and are also highly
tumorigenic when injected into mice. It is thought that
these aggressive cells are also the most invasive cells and
are able to survive and metastasize to other vital organs,
leading to fatality in patients [24–26].
Recently, using this model of invasion to isolate
pancreatic TICs, we observed significant increases in gene
expression in a large number of genes related to DNA
repair, specifically genes involved in BRCA1-mediated
DNA repair (Mathews et al., unpublished). Additionally,
various genes were identified as being upregulated as well
and can be classified as members of hereditary breast cancer
susceptibility signaling, including ATM, RAD50 and RAD51,
PTEN, and a number of genes belonging to the Fanconi
anemia family which have previously been linked to DNA
repair mechanisms [27, 28]. Functionally, we also observed
an increase in the ability of the TICs to repair DNA after
challenge with gemcitabine compared to the total population
of cells. These observations prompted us to explore the
literature to determine whether other data supported a
mechanismforincreasedDNArepairinstemcellpopulations.
1.2 Mechanisms of DNA repair
To understand the notion that stem cells display an increase
in genomic stability, it is necessary that the different DNA
repair mechanisms which cells use to maintain this stability
are described (Table 1). These mechanisms include double-
strand break repair (homologous recombination-mediated
repair and non-homologous end-joining), mismatch repair,
and nucleotide excision repair. A variety of the proteins
involved in the process of DNA repair are defined as cancer
susceptibility genes, and mutations or loss of expression in
proteins such as ATM, BRCA1, BRCA2, p53, and a
number of RAD proteins reveal that loss of heterozygosity
at their genomic regions corresponds to the onset of
sporadic breast carcinomas [29]. Our hypothesis is that in
TICs, there is an increase in the expression of these DNA
repair-related genes, therefore rendering the cells extremely
stable to genetic insult and increasing their ability to
survive and function as tumor initiators.
1.2.1 Double-strand break repair
The two major subdivisions of double-strand break repair
(DSB) include homologous recombination-mediated repair
(HRR) and non-homologous end-joining (NHEJ; reviewed
in [30]). HRR uses thousands of bases of sequence
homology either from a sister chromatid or a homologous
chromosome during S/G2 phase and is the most error-free
method of repair [30]. NHEJ, occurring during G1/S,
requires little or no sequence homology for efficient repair
and can be error-free or error-prone depending on the type
of ends that are present at the site of the DSB. A key
regulator in mediating which pathway a cell chooses to
repair broken DNA is the multifunctional protein BRCA1
(as reviewed in [29]). BRCA1 preferentially channels DSB
repair into HRR rather than NHEJ, and the process is
started by a protein complex containing MRE11, RAD50,
and NBS1, termed the MRN complex. A series of
additional steps allows RAD51 to form a nucleoprotein
filament and catalyze homologous pairing and strand
exchange with the assistance of BRCA2. During NHEJ,
an entirely different complex is formed using the KU70 and
KU80 proteins, followed by recruitment and activation of
the DNA protein kinase DNA-PKc, resulting in subsequent
activation of XRCC4 and DNA ligase IV (LIG4) [31].
Table 1 Main mechanisms of DNA repair and their contributing proteins
Non-homologous end-joining (NHEJ) KU70, KU80, DNA-PKc, XRCC4, and DNA ligase IV
Homologous recombination-mediated repair (HRR) BRCA1, BRCA2, RAD50, RAD51, MRE11, NBS1
Mismatch repair (MMR) MutSα (MSH2/MSH6), MutSβ (MSH2/MSH3), MutLα (MLH1/PMS2),
MutLβ (MLH1/MLH3), EXO1
Nucleotide excision repair (NER) DDB1, XPE, XPC-RAD23B, TFIIH, XPB, XPD, RPA
Base excision repair (BER) AP-endonuclease, DNA polymerase-β, DNA ligase III, XRCC1 DNA
polymerase-δ or -ε, PCNA, DNaseIV/FEN-1, DNA ligase I
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The mismatch repair (MMR) system repairs base–base
mismatches that result in point mutations and insertion/
deletion loops that can further result in frameshift mutations
[32]. The MMR pathway, like other repair pathways,
involves many proteins which act sequentially to repair
the damaged DNA. The mismatch is first recognized by a
protein called MutSα, which is a dimer of MSH2/MSH6 or
MutSβ, containing a dimer of MSH2/MSH3 [32, 33].
Mismatch excision is initiated by the binding of MutLα,a
dimer of MLH1/PMS2, or MutLβ, a dimer of MLH1/
MLH3. Further recruitment of the exonuclease, EXO1,
results in the sequential removal of nucleotides between an
adjacent single-strand break up to and beyond the mismatch
on the daughter strand. The DNA is then resynthesized by
DNA polymerase-δ along with PCNA and RPA and ligated
with DNA ligase [32, 33].
1.2.3 Nucleotide excision repair
The process ofnucleotideexcisionrepair(NER) isconsidered
the most versatile form of DNA repair and operates on
damaged/disruptive bases resulting from UV or oxidative
damage [31]. Two different NER pathways exist and have
substrate specificities depending on whether the damage is in
the actively transcribed strand of a gene or elsewhere in the
genome. The process global genomic NER (GG-NER)
occurs if the damage is in the actively transcribed strand of
a gene, and transcription-coupled repair (TCR) occurs if the
lesions are directly associated with errors in transcription
itself [31]. In GG-NER, two different heterodimeric proteins
bind to the DNA, recognize the damage, and initiate repair.
One of the complexes is named UV-damaged DNA-binding
protein (UV-DDB) and consists of the proteins DDB1 and
XPE. Binding of this complex then allows recruitment of
XPC-RAD23B, a step which is not required in TCR, and
permits the entry and binding of TFIIH which has ten
different subunits. Two of the subunits, XPB and XPD, are
helicases and are able to unwind the damaged DNA strand,
permitting the binding of another protein called RPA. The
gap repair proteins, RFC, PCNA, and DNA polymerase-δ
are then able to carry out new DNA synthesis and seal the
strand using DNA ligase I. TCR repairs damaged DNA more
rapidly in the transcribed regions than in non-gene regions.
In humans, TCR-NER requires all of the same proteins GG-
NER does, expect for XPE, XPC, and RAD23B, thereby
suggesting that an alternate mechanism is utilized [31].
1.2.4 Base excision repair
Base excision repair (BER) is most often used to protect
cells from damage that is caused by cellular metabolism
and by spontaneous depurinations [31]. There are two
subdivisions of BER: “short-patch repair” and “long-patch
repair.” Short-patch repair involves the repair of a single
nucleotide, and long-patch repair involves repairing between
2 and 15 nucleotides. Both pathways include DNA glyco-
sylases, endonucleases, and DNA polymerases [34]. During
the short-patch repair, after base damage, recognition occurs
by a DNA glycosylase/lyase and subsequent cleavage of the
damaged base occurs by AP endonuclease. DNA
polymerase-β will generate a repair patch and DNA ligase
III will seal the DNA with the help of the XRCC1 protein.
Long-patch repair utilizes proteins involved in DNA
replication, including DNA polymerase-δ or -ε, PCNA,
DNaseIV/FEN-1, and DNA ligase I.
The various mechanism(s) and pathways utilized by a
cell to carry out DNA repair are extensive and complicated.
DNA repair mechanism(s) are essential to the maintenance
of a normal intact stable genome, and the hypothesis that
TICs are capable of an enhanced efficiency of DNA repair
is plausible. The role of DNA repair mechanism(s) in stem
cells is a critical process necessary for stem cell regulation,
and the hypothesis that DNA repair processes in TICs are
more efficient is further investigated below (Table 2).
1.3 DNA repair in embryonic and normal stem cells
Data obtained from ES cells suggest that they have robust
mechanisms in place to preserve their genetic stability and,
compared to somatic cells, display substantially lower
mutation frequencies [30]. For example, compared to
mouse embryonic fibroblasts (MEFs), ES cells have a
100-fold lower level of mutation in the Arpt gene [35, 36].
In a similar analysis, spontaneous mutation frequencies in
the Hprt gene were not detectable in ES cells, whereas in
MEFs, the rate was in the range of 10
5 [36]. Although
suppression of mutagenesis is one mechanism that ES cells
use to maintain their genomic stability, there is much more
evidence suggesting that differences in this increased
stability are due to increases in DNA repair [30]. The
major pathway that ES cells utilize to repair damaged DNA
is DSB repair via the HRR mechanism. This is thought to
be the major pathway of repair since ES cells lack a G1
checkpoint, have short G1 and G2 cell cycle phases, and
spend the majority of time in the S-phase [37]. Lastly,
recent data demonstrate that RAD51 is a key player for
HRR in ES cells. It has been shown that when RAD51 is
deleted from ES cells, the cells are not viable; furthermore,
cells isolated from RAD51 null blastocysts are unable to
proliferate [38].
With regard to NHEJ, it is thought to play a minor role
in repairing DNA in ES cells [30]; however, the majority of
these data are from studies conducted using mouse cell
lines. Recent data using human ES cells (hESCs) demon-
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decreases throughout differentiation toward neural progen-
itor and astrocytes [39]. However, rapidly proliferating
hESCs do utilize NHEJ in a process that is independent of
ATM, DNA-PKcs, and PARP, but dependent on XRCC4.
As these cells differentiate, the rate of NHEJ progressively
increases while the fidelity of repair decreases [39, 40].
Overall, hESCs demonstrate an enhancement of DNA
repair as a method to protect their genome and display
higher levels of DNA-PKcs after irradiation, thus leading to
a highly efficient DSB repair [41].
With regards to ES cells and MMR, there are signifi-
cantly higher levels of MSH2 and MSH6 in ES cells
compared to 3T3 cells [42]. When these cells are induced to
differentiate with retinoic acid, the expression of MSH2
decreases as well. For the NER-based pathway, when ES
cells are compared to either MEFs, CHO cells, or murine
cardiomyocytes, low doses of UV radiation result in very
similar levels of repair [43]. However, at higher doses, the
ES cell repair machinery becomes saturated and the repair
remains incomplete. This is contrary to previously pub-
lished data suggesting that the NER is more efficient in ES
cells compared to terminally differentiated cells and appears
to be dependent on the cell cycle processes [44]. Although
the results from a number of studies demonstrate opposing
data, additional experiments need to be performed to
determine the role of NER in stem cell populations.
Similar to HSCs, adult stem cells remain in a fairly
quiescent state [45]. This state of quiescence is considered
to be protective since it minimizes endogenous stress caused
by cellular respiration and replication. Recent data demon-
strate that quiescent HSCs use NHEJ while proliferating
HSCs use the high-fidelity HRR mechanism [45]. It is
speculated that the use of the NHEJ mechanism in quiescent
cells renders the cells more susceptible to genomic instability
associated with misrepaired DNA, leading to loss of HSC
function and premalignant transformation. Alternatively,
proliferating cells use the HRR mechanism to decrease any
further risk of acquiring mutations. It has been proposed that
it is logical to use HRR in long-lived quiescent HSCs in
order to guard them against errors occurring during DNA
replication and damage associated with oxidative stress.
Furthermore, normal multipotent stem cells isolated from the
hair follicle bulge have two important mechanisms for
increasing their resistance to DNA damage-induced cell
death: higher expression of the anti-apoptotic gene Bcl-2 and
transient stabilization of p53 after DNA damage [46].
Investigation in keratinocyte stem cells showed increased
levels of DSBR and single-strand break repair (SSBR)
compared to progenitor cells, and further evidence shows
that FGF2 is critical to mediate this repair [47]. These data
further support that normal stem cells have evolved more
efficient DNA repair mechanisms to help increase their
overall survival compared to differentiated cells.
Table 2 Cancer types, genes and DNA repair mechanisms
Cells/cancer types Genes Mechanism Reference
Embryonic stem cells RAD51 HRR [38]
DNA-PKcs DSB [41]
MSH2, MSH6 MMR [42]
Hematopoietic stem cells (quiescent) NHEJ [45]
Hematopoietic stem cells (proliferative) HRR [45]
Normal multipotent stem cells
from hair follicle bulge
Bcl-2, p53 increase resistance DNA-damaged
induced death
[46]
Keratinocyte stem cells FGF2 DBSR, SSBR [47]
Glioma tumor-initiating cells CHK1, CHK2 Increase activation [51]
BMI-1, DNA-PK, PARP-1 Repair IR-induced DNA damage [50]
MGMT DSB, NHEJ [57]
EZH2/HOX Alkylating agent sensitivity [61–63]
PcG [64, 65]
Breast cancer cell line MCF-7 RAD51, APE1 SSBR [70]




H BRCA1 Increased Expression [73]
Metastatic malignant melanoma Higher DNA repair [67–69]
Pancreatic cancer BRCA1 BRCA1-mediated repair Unpublished,
Mathews et al.
RAD51 RAD51 DNA damage response [74]
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the extensive evidence supporting that hESCs, human and
rat HSCs, and human bone marrow-derived mesenchymal
stem cells have more efficient repair than differentiated cells
[48]. These and other studies have led us to further
investigate whether TICs are able to thrive due to an
enhancement in their DNA repair mechanisms.
1.4 DNA repair in tumor-initiating cells
Frosina [49] also suggests that DNA repair is higher in both
normal and cancer stem cells (CSCs or TICs) isolated from
the central nervous system compared to differentiated and/
or non-TICs. Bao et al. [50] have demonstrated that
CD133
+ glioma cells isolated from both human glioma
xenografts and primary patient glioblastoma specimens
preferentially activate the DNA damaged checkpoint in
response to radiation and repair IR-induced DNA damage
more effectively than the cells not expressing CD133.
Ropolo et al. [51] have shown that glioma stem cells
compared with non-stem cells have a significant increase in
the population doubling time as well as an increase in the
activation of CHK1 and CHK2 induced by IR in the
CD133
+ fractions. Although Ropolo et al. [51] did not find
a significant change or enhancement of DNA repair in their
glioma stem cell population, they speculate that it is a delay
in cell cycle via an increase in cell cycle checkpoint kinases
that allows for more time to repair DNA damage. Although
there is a discrepancy between the studies peformed by Bao
et al. [52] and Ropolo et al. [51], it is clear that the stem cell
population utilizes a unique mechanism to ensure that there
is efficient DNA repair; whether it may be an increase in
DNA repair mechanism(s) or a delay in cell cycle is still
under investigation.
To further elucidate this, McCord et al. [53] determined
that clonogenic survival curves from six CD133
+ glioblas-
toma tumor stem-like cell (TSC) lines were more radiosen-
sitive compared to the parent lines. The authors state that
the significance of these data is unclear since in vitro
radiosensitivity does not predict in vivo tumor radio-
response; yet, the data do suggest that the molecular
determinants of TSC radiosensitivity compared to total
cells differ and could serve as important therapeutic targets.
McCord et al. [53] demonstrate that CD133
+ TSCs were
able to activate the G2 checkpoint; however, they were
deficient in activating the intra-S-phase arrest. The authors
state that this could explain the relative radiosensitivity
differences; however, the S-phase checkpoint plays a critical
role in maintaining the genome, and this instability could
actually be the driving force leading to tumor development
and heterogeneity. Importantly, overall in glioblastoma TICs,
there appears to be a universal requirement for more efficient
DNA repair by the stem cell population compared to the non-
stem cell population; further experiments will decipher their
differential regulation.
Patient studies show that those diagnosed with malignant
glioblastoma multiform (GBM) have a median survival of
5–8 months, and it is thought that the inefficient treatments
available are due to resistance mechanisms acquired by
aggressive TICs, such as the enhancement in DNA repair.
Interestingly, there is evidence showing that post-irradiation
in mice, the bulk GBM tumor responds and, as expected,
the tumor shrinks [54]; however, CD133
+ cells activate the
checkpoint controls and repair damaged DNA more
efficiently than the CD133
− fractions, thus allowing for
repopulation of the tumor. TICs may actually have similar
DNA repair rates, but because they have lower levels of
proliferation and constitutive activation of the checkpoint
response, it allows for more time to repair breaks. We
hypothesize that these highly aggressive cells could be
targeted with DNA checkpoint inhibitors by increasing their
sensitivity to radiation and allowing for their destruction.
One such drug, AZD7762, produced by AstraZeneca, is an
ATP-competitive checkpoint kinase inhibitor that assists
DNA-damaging drugs by blocking the checkpoint response
(reviewed in [55]). When the drug was administered in
combination, it can block tumor formation in multiple
xenograft models where DNA-damaging agents alone
cannot [56]. The drug selectively blocks CHK1 and
CHK2, abrogates S and G2 checkpoints, and enhances the
efficacy of gemcitabine and topotecan, thus making it an
attractive therapeutic for the treatment of cancers with a
high stem cell fraction.
Recently, it was also demonstrated that the polycomb
group (PcG) protein BMI-1 co-purifies with DNA DSB
response and NHEJ proteins DNA-PK and PARP-1 in
CD133
+ GBM cells [57]. When BMI-1 is inactivated,
recruitment of the DNA repair machinery is inhibited and
the cells become increasingly radiosensitive. BMI-1 has
been implicated as a regulator of stem cell maintenance in a
number of cell lines and plays a significant role in
maintaining TICs isolated from the prostate [58]. In
addition to pharmacological inhibition of the DNA check-
points, the targeted inhibition of BMI-1 combined with
radiation could possibly lead to the destruction of GBM
stem cells. Furthermore, another recent study demonstrated
that when DNA-PKc levels were decreased with short
hairpin RNA, glioma-initiating cells (GICs) were radiosensi-
tized and underwent autophagy compared to cells expressing
much higher levels of the enzyme [59]. Since DNA-PKc is a
catalytic subunit, these data support the hypothesis that TICs
in fact have more efficient DNA repair capabilities.
Alternatively, methylation of the O
6-methylguanine
DNA methyltransferase (MGMT) is the first predictive
marker for benefit from alklyating agent therapy in the
treatment of glioblastoma [60, 61]. This enzyme reverses
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6 position of guanine, thus neutralizing
the cytotoxic effect of alkylating agents such as temozolo-
mide (TMZ). In this situation, if the DNA repair gene
MGMT is actually methylated and thus not expressed, the
patient responds to the therapy. Recent investigation
determined that in MGMT methylated glioblastoma, pro-
moter methylation is also highly enriched in GICs [61]. In
contrast, another study demonstrated that compared to
established glioma cell lines, neurosphere-forming GICs
expressed higher levels of MGMT [62]; furthermore, when
GBM-initiating cells were transduced with a shRNA to
MGMT, the cells could be sensitized to TMZ treatment by
decreasing both their ability to undergo DNA repair and
efflux of the drug [63]. In the pediatric glioblastoma cell
line KNS42, however, it was recently determined that these
cells remain resistant to temozolmide treatment despite the
absence of MGMT expression [60], thereby demonstrating
that an MGMT-independent mechanism is able to regulate
GIC survival. Although expression of MGMT leads to
temozolmide resistance, regulation of this DNA repair
pathway and maintenance of “stem-ness” is much more
complex than once originally believed.
Furthergeneexpressionanalysisdeterminedthatexpression
of HOX genes were significantly increased in a number of
resistant cell lines and is associated with shorter survival in
pediatric high-grade glioma patients [60]. Although HOX
genes are known to play a role in the developing embryo and
in the progression of adult glioblastoma, their role in
regulating resistance to alkylating agents is unknown. HOX
genes have recently been connected to the PcG proteins, such
as EZH2 [64]. PcG proteins were originally identified in the
fruit fly as repressors of the HOX genes; however, functional
EZH2 expression is essential for the maintenance of
glioblastoma cancer stem cells [65]. Furthermore, expression
of EZH2 directly correlates with the progression of disease
and is a member of the “death-from-cancer” signature, which
is described in greater detail later in the review [66].
In human metastatic malignant melanoma, it has recently
been shown that metastasis is associated with higher
expression of DNA repair genes and that these aggressive
cells are highly efficient at repairing damage caused by
cytotoxic treatment regimes [67–69]. A majority of the
repair genes overexpressed were in primary tumors with a
poor prognosis; therefore, the authors speculate that
primary melanoma cells are capable of undergoing metas-
tasis and replication by using a fast and error-free method.
A review published by the same authors stated a relatively
new hypothesis similar to the one we are presenting here in
relation to TICs: that the overexpression of DNA repair
genes is associated with the onset of metastasis [69]. The
authors stated that DNA repair is vital for normal life
because defects in DNA repair activity are associated with a
shorter life span as well as predispositions to cancer and/or
aging. However, from a meta-analysis using the Gene
Ontology database, they found that DNA repair pathways
are overexpressed in a large set of primary tumors
associated with a high risk of distant metastasis [61]. With
regard to our hypothesis that DNA repair mechanisms are
much more efficient in TICs, the meta-analysis performed
supports this as there is evidence supporting the idea that
TICs are responsible for metastasis.
The role of TICs in connection with enhanced DNA
repair has also been demonstrated in other cancer types. In
the breast cancer cell line MCF-7, it was recently shown
that TICs isolated by mammosphere formation assays have
a more active DNA SSBR pathway demonstrated by
increased levels of RAD51 foci and expression of the
APE1 protein compared to total cells [70]. Although no
changes in DSBR were observed, the mammospheres
appear to bypass the requirement to phosphorylate H2AX.
The authors state that the mammospheres had a reduction in
their propensity to undergo senescence due to an increase in
telomerase activity and lower levels of p21 expression.
Additionally, other groups have reported that activation of
AKT and canonical WNT signaling in breast TICs results in
an increased efficiency of DNA repair [71, 72].
The most significant data supporting TIC maintenance
and DNA repair from the mammary gland are from a study
conducted by Zhang et al. in 2008 [73]. The putative TICs




H, and compared to non-TICs, these
expressed higher levels of genes related to the DNA
damage response and repair, as well as genes involved in
epigenetic regulation of self-renewal [73]. The upregulated
genes included Brca1, which supports a recent finding in
our laboratory where we have determined that both invasive
cells and TICs have increased levels of a larger number of
genes related to DNA repair in a pancreatic cancer cell
model. Specifically, these DNA repair genes are involved in
the BRCA1-mediated DNA repair pathway (Mathews et al.,
unpublished). Functionally, we observed an increase in the
ability of pancreatic TICs to repair DNA after challenge
with gemcitabine compared to the total population of cells.
In line with our results, a previous investigation with
different pancreatic cancer cell lines determined that an
increased sensitivity to gemcitabine could be obtained by
treating the cells with a CHK1 inhibitor, and this was
accomplished by decreasing the RAD51 DNA damage
response [74]. The results from this study and ours
prompted us to investigate whether other forms of
aggressive cancers also demonstrate an increase in expres-
sion of the DNA repair genes we identified.
To further investigate the role of DNA repair genes in
TICs, we took our gene list from the TICs derived from
pancreatic cells and a “death-from-cancer” gene list [75].
This “death-from-cancer” gene list contains a number of
Cancer Metastasis Rev (2011) 30:185–197 191DNA repair genes, and we utilized the Oncomine database
to determine whether there was a similarity between the
DNA repair genes from this list and TICs from pancreatic
cells. The death-from-cancer signature contains elevated
expression of genes related to DNA repair and cell cycle
control in both metastatic breast and prostate cancers. In
addition to displaying elevated expression of DNA repair
and cell cycle genes, these aggressive cancer cells manifest
a stem cell-like expression profile very closely related to a
number of genes expressed in TICs from the prostate [58].
Expression of two “death-from-cancer” genes, EZH2 and
BMI-1, were also found to be significantly increased in the
mouse mammary gland TICs previously mentioned [73].
Thus, we selected DNA repair and cell cycle-related genes
from the “death-from-cancer” gene list and observed
significantly increased gene expression and/or DNA copy
number of these DNA repair genes in aggressive pancreatic
cancers [76] (Mathews et al., unpublished), and various







Fig. 2 Oncomine analysis of DNA repair genes and “death-from-
cancer” genes in metastatic prostate tissues compared to primary
tumor tissues The heat maps represent raw data from the a number of
studies comparing gene expression levels of DNA repair genes in 1
primary prostate tumor tissues to 2 metastatic tissues. The p value
represents Student’s t tests comparing primary and metastatic
expression. The fold change in expression, the gene name, and the
reporter ID from the position on the array are provided as well. Genes
demonstrating increases in metastatic tissues are shown in red. Studies
were conducted by Yu et al. [66]( a), Lapointe [79]( b), LaTulippe et
al. [80]( c), Vanaja et al. [78]( d), Varambally et al. [81]( e), and
Magee et al. [77]( f)
192 Cancer Metastasis Rev (2011) 30:185–197cancer types as well (Figs. 2 and 3). We demonstrate a trend
of increased expression of DNA repair genes in cancers
from the prostate [66, 77–81] (Fig. 2a–f), the cervix [82],
head and neck [83], brain [84], the kidney [85], and the
bladder [86]. In Fig. 3a, we demonstrate that there are
significant increases in DNA repair-related genes in
cervical cancer compared to the cervix uteri. Figure 3b
compares the expression between hypopharynx, oropharynx,
and the more aggressive hypopharygenal squamous cell
carcinoma. Figure 3c shows the expression of these genes
inganglioneuroblastoma,ganglioneuroma,andneuroblastoma.
Figure 3d focuses on the increase of these genes in the
aggressive renal Wilms’ tumors in comparison to renal
carcinoma, renal lipoma, renal oncocytoma, renal sarcoma,
and rhabdoid tumor of the kidney. Lastly, we show a
significant increase of these genes in infiltrating bladder
urothelial carcinoma compared to the bladder (Fig. 3e).
Figures 2 and 3 demonstrate that there is a common trend
ofincreasedgeneexpressionofDNA repair-relatedgenes and
cell cycle genes in various carcinomas, specifically cancers
associated with aggressiveness. Although this connection
between TICs and the aggressive nature of each tumor type
listed has not been 100% elucidated, there is overwhelming
evidence derived from Oncomine strongly suggesting an
increased efficiency in DNA repair in these aggressive
samples.
As seen in the data established from the Oncomine
datasets, metastatic prostate cancer has a unique signature
of increased DNA repair-related genes. We have previously
shown that prostatospheres derived from both LNCaP and
primary patient cell lines (PCSC1, PCSC2, and PCSC3) are
representative of the TIC population and exhibit the ability
to initiate tumors in vivo [19]. Upon further analysis of
these prostatospheres using Agilent’s whole genome gene
expression array and Ingenuity Pathway Analysis (IPA), we
compared prostatospheres to the adherent population and
discovered that a top function for significantly upregulated
genes, at least ≥1.8-fold change, for all cell lines, was DNA
replication, recombination, and repair. The molecules
involved in these pathways which were significantly
upregulated in our prostatospheres are organized by
function in Electronic supplementary material Tables 1–4.
1.  Renal Carcinoma 
2.  Renal Lipoma  
3.  Renal Oncocytoma 
4.  Renal Sarcoma 
5.  Renal Wilms Tumor
6.  Rhabdoid Tumor of the Kidney 
Cervix Uteri         Cervical Cancer  1.  Hypopharynx 
2.  Oropharynx 
3.  Hypopharyngeal Squamous Cell Carcinoma 
1.  Ganglioneuroblastoma
2.  Ganglioneuroma 
3.  Neuroblastoma
Bladder                               Infiltrating Bladder Urothelial Carcinoma  
a. b. c.
d. e.
Fig. 3 Oncomine analysis of DNA repair genes and “death-from-
cancer” genes in other cancers. The heat maps represent raw data from
the a number of studies comparing gene expression levels of DNA
repair genes in normal tissue and cancer tissues, as well as more
aggressive forms of a number of the cancers shown. The p value
represents Student’s t test comparing primary and metastatic expres-
sion. The fold change in expression, the gene name, and the reporter
ID from the position on the array are provided as well. Genes
demonstrating increases in cancerous tissues are shown in red. Studies
were conducted by Pyeon et al. [82] in the cervix (a), Schlingemann et
al. [83] in the head and neck (b), Albino et al. [84] in the brain (c),
Yusenko et al. [85] in the kidney (d), and Sanchez-Carbayo et al. [86]
in the bladder (e)
Cancer Metastasis Rev (2011) 30:185–197 193We further used IPA to analyze the top canonical pathways
used by the significantly upregulated genes. In the case of
LNCaP prostatospheres and DNA repair mechanisms, IPA
reports that the role of CHK proteins in cell cycle
checkpoint control is a top canonical pathway (Fig. 4a).
Interestingly, for all primary patient cell lines, PCSC1,
PCSC2, and PCSC3, a top canonical pathway conserved in
prostatospheres compared to the adherent population is the
role of BRCA1 in DNA damage response, similar to what
was seen in our pancreatic invasive and TIC cells (Fig. 4b,
c). Thus, we see a conservation of increased DNA repair
mediated by BRCA1 in both pancreatic and prostate TICs;
hence, we propose that this be further examined in other
cancer models.
a. LNCaP b. PCSC1
d. PCSC3 c. PCSC2
Fig. 4 Ingenuity analysis demonstrating significant changes in DNA
replication, recombination, and repair pathways in prostatospheres.
Genes highlighted in red demonstrate a significant increase in
expression in prostatospheres compared to total cells. a LNCaP
prostatospheres show an increase in CHK proteins in cell cycle
checkpoint control. In PCSC1 (b), PCSC2 (c), and PCSC3 (d),
prostatospheres have an increase in genes demonstrating a role of
BRCA1 in DNA damage response
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The existence of TICs has been a topic of heated debate for
the last few years within the field of cancer biology. The
data presented in this review summarize the results found
by our lab and others demonstrating that TICs have an
increase in their genomic stability. We hypothesize that this
increase in DNA repair mechanisms could allow for TIC
survival while the bulk population of tumor cells dies in
response to treatment. Using the Oncomine database and
IPA, we demonstrated that there is a trend in the increased
expression of DNA repair-related and cell cycle genes in
this specific population. TICs are defined by their ability to
self-renew, differentiate, and initiate tumor formation. TICs
are also associated with aggressiveness and are believed to be
responsible for both metastasis and chemo- and radioresist-
ance. The mechanism(s) by which TICs function to carry out
these processes are under intense investigation. However, we
speculate that the ability of a TIC to have enhanced and
increased DNA repair efficiency is critical in the maintenance
of TICs and may function in their ability to resist traditional
anticancer treatments. We believe that these data will greatly
impact the development of new therapies being designed to
eradicate these highly aggressive cancers.
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